Every 10-Q that Forte Biosciences Inc (FBRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow FBRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FBRX filings page.
Forte Biosciences, Inc. reported a larger net loss while advancing its lead autoimmune candidate FB102 and agreeing to be acquired. For the six months ended June 30, 2026, net loss was $45.5 million compared with $26.9 million a year earlier, driven mainly by higher FB102 clinical and manufacturing spend. Research and development expenses rose to $42.8 million, while general and administrative expenses declined to $4.2 million helped by $4.8 million of insurance recoveries related to prior litigation.
Cash, cash equivalents and short‑term investments totaled $198.5 million, supported by a $172.5 million April 2026 equity offering. Management believes this liquidity funds operations for at least 12 months. The company remains pre‑revenue with an accumulated deficit of $268.8 million.
FB102 generated positive Phase 1b data in celiac disease and non‑segmental vitiligo, and a Phase 1b alopecia areata study and a Phase 2 celiac trial are ongoing with topline data expected in the second half of 2026. On July 26, 2026, Forte agreed to be acquired by argenx BV via a cash tender offer at $77.00 per share followed by a merger, subject to customary conditions and a potential $65 million termination fee.
Forte Biosciences, Inc. reported a net loss of $22.1 million for the three months ended March 31, 2026, wider than the prior-year period, as it ramped spending on its lead autoimmune antibody FB102.
Research and development expenses rose to $20.5 million, driven by a Phase 2 trial in celiac disease and Phase 1b trials in non-segmental vitiligo and alopecia areata, while general and administrative expenses declined to $2.0 million, helped by a $2.3 million interim insurance recovery related to litigation defense costs. Cash and cash equivalents were $58.2 million as of March 31, 2026, with operating cash outflows of $18.8 million in the quarter.
After quarter-end, Forte strengthened its balance sheet through an April 2026 equity offering generating $172.5 million in gross proceeds and $162.1 million in net proceeds before other offering expenses, and believes this funding, together with existing cash, will support operations for at least twelve months from the filing date while advancing FB102 through ongoing clinical trials.
Forte Biosciences (FBRX) filed its Q3 2025 10‑Q, reporting continued investment in FB102 and a larger cash position. The company recorded a Q3 net loss of $17.7 million, driven by research and development expenses of $15.2 million and general and administrative costs of $3.2 million.
Cash and cash equivalents were $93.4 million as of September 30, 2025, supported by a June public offering that raised gross proceeds of $75.0 million and an additional $1.8 million from an underwriter option in July. Net cash used in operating activities for the nine months was $34.4 million.
FB102 advanced clinically: a Phase 2 celiac study began in July 2025, and the FDA approved an IND in November 2025 for a U.S. arm. Earlier, the celiac Phase 1b showed statistically significant histology and symptom improvements. Vitiligo and alopecia areata Phase 1b studies are ongoing. Shares outstanding were 12,526,935 as of November 7, 2025; 5,304,511 pre‑funded warrants remained outstanding as of quarter‑end.